Literature DB >> 23578349

Predictors of one-year mortality after transcatheter aortic valve implantation for severe symptomatic aortic stenosis.

Ralf Zahn1, Ulrich Gerckens, Axel Linke, Horst Sievert, Philipp Kahlert, Rainer Hambrecht, Stefan Sack, Mohamed Abdel-Wahab, Ellen Hoffmann, Rudolf Schiele, Steffen Schneider, Jochen Senges.   

Abstract

Transcatheter aortic valve implantation (TAVI) is already an accepted option to treat elderly patients with severe symptomatic aortic stenosis who are inoperable or at high surgical risk. However, short- and long-term mortality after TAVI remains an important issue, raising the need to further improve the technology of TAVI as well as to identify patients who will not benefit from TAVI. A total of 1,391 patients treated with TAVI at 27 hospitals were included in the German Transcatheter Aortic Valve Interventions - Registry. One-year follow-up data were available for 1,318 patients (94.8%), with a mean follow-up period of 12.9 ± 4.5 months. One-year mortality was 19.9%. Survivors and nonsurvivors showed multiple differences in patient characteristics, indications for interventions, preintervention and interventional characteristics, and postintervention events. A higher logistic European System for Cardiac Operative Risk Evaluation score was associated with higher 1-year mortality (p <0.0001). Cox proportional-hazards analysis revealed the following independent predictors of mortality: among preintervention findings: previous mitral insufficiency ≥II° (p = 0.0005), low-gradient aortic stenosis (p = 0.0008), previous decompensation (p = 0.0061), previous myocardial infarction (p = 0.0138), renal failure (p = 0.0180), previous New York Heart Association class IV (p = 0.0254), and female gender (p = 0.0346); among procedural factors: intraprocedural conversion to surgery (p = 0.0009), peri-intervention stroke (p = 0.0003), and residual aortic insufficiency ≥II° (p = 0.0022); and among postprocedural events: postintervention myocardial infarction (p = 0.0009) and postintervention pulmonary embolism (p = 0.0025). In conclusion, 1-year mortality after TAVI was 19.9% in this series. Patient characteristics and procedural as well as postintervention factors associated with mortality were identified, which may allow better patient selection and better care for these critically ill patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23578349     DOI: 10.1016/j.amjcard.2013.03.024

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  33 in total

1.  2020 update of the Austrian Society of Cardiology (ÖKG) and the Austrian Society of Cardiac Surgery (ÖGHTG) on the position statement of the ÖKG and ÖGHTG for transcatheter aortic valve implantation 2011.

Authors:  Gudrun Lamm; Matthias Hammerer; Uta C Hoppe; Martin Andreas; Rudolf Berger; Ronald K Binder; Nikolaos Bonaros; Georg Delle-Karth; Matthias Frick; Michael Grund; Bernhard Metzler; Thomas Neunteufl; Philipp Pichler; Albrecht Schmidt; Wilfried Wisser; Andreas Zierer; Rainald Seitelberger; Michael Grimm; Alexander Geppert
Journal:  Wien Klin Wochenschr       Date:  2021-03-23       Impact factor: 1.704

Review 2.  TAVR Vs. SAVR in Intermediate-Risk Patients: What Influences Our Choice of Therapy.

Authors:  Sasha Still; Molly Szerlip; Michael Mack
Journal:  Curr Cardiol Rep       Date:  2018-08-09       Impact factor: 2.931

3.  Sex differences in outcomes with transcatheter aortic valve replacement.

Authors:  Feng Qian; Edward L Hannan
Journal:  Ann Transl Med       Date:  2017-08

4.  The impact of transcatheter aortic valve implantation on quality of life: results from the German transcatheter aortic valve interventions registry.

Authors:  Janine Biermann; Martin Horack; Philipp Kahlert; Steffen Schneider; Georg Nickenig; Ralf Zahn; Jochen Senges; Raimund Erbel; Jürgen Wasem; Till Neumann
Journal:  Clin Res Cardiol       Date:  2015-04-21       Impact factor: 5.460

Review 5.  The transition from transesophageal to transthoracic echocardiography during transcatheter aortic valve replacement: an evolving field.

Authors:  Menhel Kinno; Eric P Cantey; Vera H Rigolin
Journal:  J Echocardiogr       Date:  2018-11-21

Review 6.  Efficacy of transcatheter aortic valve implantation in patients with aortic stenosis and reduced LVEF. A systematic review.

Authors:  X Luo; Z Zhao; H Chai; C Zhang; Y Liao; Q Li; Y Peng; W Liu; X Ren; Q Meng; C Chen; M Chen; Y Feng; D Huang
Journal:  Herz       Date:  2015-02-26       Impact factor: 1.443

7.  Effect of gender differences on 1-year mortality after transcatheter aortic valve implantation for severe aortic stenosis: results from a multicenter real-world registry.

Authors:  Mohammad A Sherif; Ralf Zahn; Ulrich Gerckens; Horst Sievert; Holger Eggebrecht; Rainer Hambrecht; Stefan Sack; Gert Richardt; Steffen Schneider; Jochen Senges; Johannes Brachmann
Journal:  Clin Res Cardiol       Date:  2014-03-06       Impact factor: 5.460

8.  A Glimpse into the Future: In 2020, Which Patients will Undergo TAVI or SAVR?

Authors:  Crochan J O'Sullivan; Peter Wenaweser
Journal:  Interv Cardiol       Date:  2017-05

9.  Impact of Mitral Regurgitation on Clinical Outcomes After Transcatheter Aortic Valve Implantation.

Authors:  Crochan J O'Sullivan; David Tüller; Rainer Zbinden; Franz R Eberli
Journal:  Interv Cardiol       Date:  2016-05

Review 10.  Worldwide TAVI registries: what have we learned?

Authors:  Stephan Haussig; Gerhard Schuler; Axel Linke
Journal:  Clin Res Cardiol       Date:  2014-03-20       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.